Entegrion, Inc.
Entegrion is a life sciences company dedicated to providing innovative solutions to improve clinicians’ ability to effectively manage hemostasis in patients. They develop patented technologies to overcome limitations in storage, safety, and availability of blood-derived products, collaborating with leading medical research institutions. Their products are designed for both civilian and military medicine, with significant funding from the U.S. Department of Defense. Entegrion's focus includes developing blood products like Resusix™ and diagnostic systems such as the Point of Care Coagulation Monitoring system, aiming to enhance patient outcomes in various clinical settings.
Industries
Nr. of Employees
small (1-50)
Entegrion, Inc.
Entegrion, Inc. Imperial Business Park 4819 Emperor Boulevard, Suite 400 Durham, NC 27703
Patents
Products
Portable viscoelastic coagulation monitoring system
A portable, near-patient viscoelastic testing instrument that provides automated, real-time assessment of whole-blood coagulation without reagents or sample pre-treatment; designed for emergency, surgical, critical care, and pre-hospital use. CE marked for sale in regions accepting the CE mark.
Dehydrated pathogen-reduced human plasma for transfusion
Spray-dried, solvent-detergent–treated dehydrated human plasma product designed to serve as a substitute for fresh frozen plasma in certain clinical applications; developed to reduce infectious risk and enable extended shelf life and deployability.
Freeze-dried platelet-derived hemostatic agent
A shelf-stable, freeze-dried hemostatic product derived from platelets intended for rapid rehydration and infusion to treat bleeding due to low platelet counts or dysfunction (preclinical development described).
Portable viscoelastic coagulation monitoring system
A portable, near-patient viscoelastic testing instrument that provides automated, real-time assessment of whole-blood coagulation without reagents or sample pre-treatment; designed for emergency, surgical, critical care, and pre-hospital use. CE marked for sale in regions accepting the CE mark.
Dehydrated pathogen-reduced human plasma for transfusion
Spray-dried, solvent-detergent–treated dehydrated human plasma product designed to serve as a substitute for fresh frozen plasma in certain clinical applications; developed to reduce infectious risk and enable extended shelf life and deployability.
Freeze-dried platelet-derived hemostatic agent
A shelf-stable, freeze-dried hemostatic product derived from platelets intended for rapid rehydration and infusion to treat bleeding due to low platelet counts or dysfunction (preclinical development described).
Services
Management and execution of defense- and government-funded product development programs, including contract deliverables, coordination with research institutions, and clinical study support.
Management and execution of defense- and government-funded product development programs, including contract deliverables, coordination with research institutions, and clinical study support.
Expertise Areas
- Point-of-care coagulation diagnostics
- Transfusion product development
- Pathogen-reduction and plasma processing
- Clinical trial execution for biologics (IND through Phase 3)
Key Technologies
- Viscoelastic coagulation testing
- Reagent-free whole-blood diagnostics
- Spray-drying of plasma
- Solvent-detergent pathogen reduction
News & Updates
The U.S. Office of Naval Research awarded Entegrion $1.9 million to fund research on blood products and related technologies, including the development of a multi-functional resuscitation fluid and Phase 1 studies for Resusix™.
Entegrion received a contract from the Department of Defense valued up to $43.7 million for the clinical development of Resusix™, a dehydrated pathogen-inactivated human plasma product.
Entegrion achieved CE mark for its portable coagulation monitoring system, enabling its marketing in Europe and other regions accepting CE Marked products.
Entegrion announced the addition of Brian Gibler to its board of directors, bringing expertise in emergency medicine.
Dr. Pierre Noel, a professor at Mayo Clinic College of Medicine with expertise in hematology and military medicine, was appointed to Entegrion's board.
CE Mark for Point of Care System for Blood Coagulation Monitoring
Regulatory clearance in Europe for Entegrion’s portable coagulation testing device.
The U.S. Office of Naval Research awarded Entegrion $1.9 million to fund research on blood products and related technologies, including the development of a multi-functional resuscitation fluid and Phase 1 studies for Resusix™.
Entegrion received a contract from the Department of Defense valued up to $43.7 million for the clinical development of Resusix™, a dehydrated pathogen-inactivated human plasma product.
Entegrion achieved CE mark for its portable coagulation monitoring system, enabling its marketing in Europe and other regions accepting CE Marked products.
Entegrion announced the addition of Brian Gibler to its board of directors, bringing expertise in emergency medicine.
Dr. Pierre Noel, a professor at Mayo Clinic College of Medicine with expertise in hematology and military medicine, was appointed to Entegrion's board.
CE Mark for Point of Care System for Blood Coagulation Monitoring
Regulatory clearance in Europe for Entegrion’s portable coagulation testing device.